Related Experiment Video
Updated: Dec 4, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Ampicillin Dose for Early and Late-Onset Group B Streptococcal Disease in Neonates
1Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin.
Insights
New guidelines offer ampicillin dosing for neonatal group B streptococcal disease, but evidence is lacking for meningitis treatment. High doses may increase seizure risk.
Area of Science:
- Neonatal pharmacotherapy
- Infectious disease management
- Pediatric pharmacology
Background:
- Ampicillin is a primary treatment for neonatal group B streptococcal (GBS) infections.
- Recent American Academy of Pediatrics (AAP) guidelines updated ampicillin dosing for GBS bacteremia and meningitis.
- The rationale and evidence supporting these updated dosing recommendations were not explicitly provided.
Purpose of the Study:
- To review the literature on ampicillin pharmacokinetics (PK), pharmacodynamics (PD), and safety in neonates.
- To identify the evidence supporting current ampicillin dosing recommendations for GBS disease in neonates.
- To evaluate the safety and efficacy of high-dose ampicillin for neonatal meningitis.
Main Methods:
- Literature search for studies on ampicillin PK, PD, and safety in neonates.
- Analysis of existing publications supporting the 2018 Red Book and 2019 AAP guidelines.
- Review of studies on ampicillin cerebrospinal fluid concentrations and associated adverse events.
Main Results:
- Evidence supports ampicillin dosing for neonatal GBS bacteremia, with adjustments for postnatal age.
- No direct evidence was found to support the increased ampicillin dosing recommendations for neonatal GBS meningitis.
- A single study on cerebrospinal fluid ampicillin concentrations suggested lower doses than currently recommended, raising concerns about supratherapeutic levels and seizure risk.
Conclusions:
- Current ampicillin dosing for neonatal GBS meningitis lacks robust supporting evidence.
- High-dose ampicillin for meningitis may lead to adverse events, including seizures, without proven efficacy.
- Further research is needed to establish optimal and safe ampicillin dosing strategies for neonatal GBS meningitis.
Abstract:
Ampicillin is frequently used in neonates for early- and late-onset group B streptococcal (GBS) disease. In 2019, the American Academy of Pediatrics (AAP) published guidelines for GBS which included updated dosing recommendations for ampicillin for bacteremia and provided specific dosing recommendations for meningitis. The dosing recommendations in the guidelines were based off the 2018 Report of the Committee on Infectious Diseases (i.e., Red Book), which differed from the 2015 Red Book. For bacteremia, no dosing changes were recommended for ampicillin dosing in neonates ≤ 7 days of postnatal age (PNA), but less frequent dosing intervals were recommended for neonates > 7 days PNA. For meningitis, increased dosing recommendations were provided in the update. However, the rationale and supporting evidence for these changes were not provided. A literature search was performed to review articles pertaining to the pharmacokinetics (PK), pharmacodynamics (PD) and safety of ampicillin in neonates. The ampicillin dosing recommendations in the AAP guidelines were mainly supported by a 2014 publication that evaluated the PK and PD of ampicillin in neonates with gestational age (GA) of 24 to 41 weeks and PNA of 0 to 25 days. The proposed dosing from this study for bacteremia is included in the 2018 Red Book and 2019 guidelines. For meningitis, no supporting evidence was identified for the dosing recommendations in the 2018 Red Book and 2019 guidelines. Only one study has evaluated ampicillin concentrations in cerebrospinal fluid, but proposed dosing from this study was much lower than that included in the guidelines. The high ampicillin doses for GBS meningitis should be used with caution, as high ampicillin concentrations have been associated with seizures and no studies have evaluated efficacy of this dosing strategy. The purpose of this review is to identify key pieces of literature regarding dosing recommendations and safety of ampicillin in neonates. KEY POINTS: · Recent guidelines provide dosing recommendations for ampicillin, but the supporting evidence is not included.. · Literature supporting evidence for ampicillin dosing for bacteremia is available, but not for dosing for meningitis.. · Recommended meningitis dose may result in supratherapeutic concentrations and increase seizure risk..
Related Concept Videos
Drug Dosing: Infants and Children
Acute Pyelonephritis II: Diagnostic Studies and Management
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Estimation of k and VD of Aminoglycosides

